Skip to content

Ultrasound-Guided T2 Erector Spinae Plane Block Versus Intercostobrachial Block in AV Fistula Surgery.

Ultrasound-Guided T2 Erector Spinae Plane Block Versus Intercostobrachial Block as Adjunct to Supraclavicular Brachial Plexus Block in AV Fistula Surgery.

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07754357
Acronym
ICBN/ESP
Enrollment
110
Registered
2026-08-10
Start date
2026-07-21
Completion date
2026-12-20
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD (End Stage Renal Disease)

Keywords

AVF superficialization, Intercostobrachial block

Brief summary

This study aims to determine whether ultrasound guided ESP block at 2nd thoracic vertebrae is non inferior to ultrasound guided ICBN block as adjunct to supraclavicular brachial plexus block in achieving complete sensory blockade of the medial upper arm during AVF superficialization

Detailed description

Arteriovenous fistula (AVF) superficialization is an essential procedure for patients with end-stage renal disease . The supraclavicular brachial plexus block is commonly used for upper extremity surgeries .Because the ICBN originates from the T2 nerve root below the C5-T1 nerve roots comprising the brachial plexus, brachial plexus blocks are ideally supplemented with an ICBN infiltration block for medial upper arm coverage.The ICBB requires precise ultrasound guidance to target the ICBN, which is small and variably located, making it technically challenging and time-intensive. ESP block at T2 level can provide broad coverage, ease of Performance, superficial injection and requiring less technical expertise compared to the ICBB . The patients are randomly allocated into 2 groups : 1. Erector spinae plane block group (Group ESP): will receive 10 ml of 0.5% bupivacaine injected into the erector spinae plane at T2 level under ultrasound guidance. 2. Intercostobrachial block group (Group ICBB): will receive 10 ml of 0.5% bupivacaine injected around intercostobrachial nerve under ultrasound guidance. • Standard Supraclavicular Brachial plexus Block will be performed for all patients using 20 ml of 0.5% bupivacaine under ultrasound guidance.

Interventions

1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.

PROCEDUREUltrasound Guided Erector Spinae Plane Block at T2 level

1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle(Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .

Sponsors

Fatma Hatem Mokhtar
Lead SponsorOTHER
Aswan University Hospital
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* • Adults scheduled for upper extremity surgeries under regional anesthesia. * Age: 18-65 years. * American society of Anesthesiologists (ASA) III. * Body Mass Index (BMI) \< 35 kg/m².

Exclusion criteria

* •Allergy to local anesthetics. * Coagulopathy or infection at injection sites. * Pre-existing neuropathy or significant psychiatric disorders. * Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients achieving complete sensory blockade during AVF superficializationbaseline then at 15,30,60,120 minutes intraoperative assessment for vital signs and sensory blockadeNo discomfort and no need for sedation or conversion to general anesthesia

Secondary

MeasureTime frameDescription
Time to achieve complete sensory blockade.Time for complete sensory blockade in minutes within 30 minutesHow much time required to achieve complete sensory blockade in minutes
Patient's satisfaction (assessed using Likert scale).At the first 24 hoursPatient satisfaction was evaluated using a five-point Likert scale (1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, and 5 = very satisfied)
Total opioid consumption in 24 hoursin the first 24 hoursTotal opioid consumption in 24 hours postoperative in mg /kg
The visual analog scale(VAS)in the first 12 hoursmeasure a patient pain intensty ,commonly used interpretation is 0:no pain,1-3 :mild pain.4-6:moderate pain,7-10 :sever pain

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026